Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Multi-sensing tool for Minimally Invasive Surgery (PALPABLE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Digital, Industry and Space
Theme: Digital
Destination: Digital & Emerging Technologies for Competitiveness and Fit for the Green Deal
Action type: Research and Innovation actions
Partnership: Photonics (co-programmed)
Countries involved: Greece,United Kingdom,Spain,Italy,Germany,Netherlands,France
Call: Advanced multi-sensing systems (Photonics Partnership) (RIA) (HORIZON-CL4-2022-DIGITAL-EMERGING-01, 2022)
Start date: 2023-01-01
End date: 2026-12-31
Duration (months): 48.0
Total project cost (EUR): 2909336.25
EU funding (EUR): 2909336.0
Participants: 10
Project status: SIGNED

PALPABLE introduces a new generation of MIS (Minimally Imvasive Surgery) tools: a novel tactile sensing probe as a palpation tool for identification and visualization of tissue abnormalities. MIS has several advantages (reduced tissue damage, postoperative analgesic requirements & blood loss, decreased hospitalization time, better cosmetic results), but there is limited or none visual, haptic, and tactile feedback in-situ, along with issues of tool dexterity. These issues can lead to accidental tissue damage. The probe (diam. 5mm, length 15-20mm) incorporates multiple sensing modalities and a thin, flexible, pneumatically actuated end-effector (3DOF, 180deg) with distributed sensors for distributed tactile sensing. The probe consists of the photonic sensing elements and a sphere held at the end of a circular tunnel by a steady flow of air. The sphere is free to rotate in all directions and can move into the channel when pressed against the airflow. When rolling over tissue, the displacement depends on the tissue’s stiffness and is picked up by the optical fibre above it. Optical intensity variation in the sensing element is used to identify tissue stiffness variations. The principle of measurement used is extrinsic light intensity modulation provided through optical fibres. A non-planar photonics circuit (200μm waveguide, 8bit colour depth) for haptic sensor array is developed and interfaced with the probe; this circuit will be engraved on ultra-thin polymeric foil. The foil sensing elements are distributed around & along the probe for multiple sensor inputs for palpation (i.e., stiffness), distance and curvature that are then fused to provide the overall tissue situation. Using thin foils allows for ease of integration with the probe and a straightforward manufacturing process to enable low cost in large volumes. The end effector is made from disposable or sterilizable materials, both options will be explored for recyclability or reusability respectively.

Keywords: palpation sensing,tactile sensing,minimally invasive surgery,pneumatic actuation,soft robotics
Addressing the Environmental Impacts Of Food Loss And Waste Prevention And Its Rebound Effects (PRECIOUS)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Food, Bioeconomy Natural Resources, Agriculture and Environment
Theme: Bio-Environment
Destination: Fair, healthy and environmentally-friendly food systems from primary production to consumption
Action type: Research and Innovation actions
Countries involved: Spain,Austria,Greece,Netherlands,Germany,Belgium,Denmark,Italy,Poland,Lithuania,Hungary
Call: Preventing and reducing food waste to reduce environmental impacts and to help reach 2030 climate targets (HORIZON-CL6-2024-FARM2FORK-01, 2024)
Start date: 2024-10-01
End date: 2028-09-30
Duration (months): 48.0
Total project cost (EUR): 4495537.5
EU funding (EUR): 4495537.5
Participants: 18
Project status: SIGNED

If food loss and waste (FLW) were a country, it would be the third leading cause of greenhouse gas emissions. FLW also burdens waste management systems and exacerbates food insecurity, , contributing significantly to the three global crises of climate change, nature and biodiversity loss, and pollution and waste. PRECIOUS, an transdisciplinary alliance of 20 entities from 11 EU countries, believes that reliable data on the environmental impacts of FLW is crucial for accelerating EU progress towards climate targets and reducing environmental impacts (including biodiversity) across the food supply chain. The project´s collective understanding is that the challenge goes beyond measuring the amount of food saved or CO2 emissions. When food is wasted, valuable and limited resources such as water, land use, and energy are lost, while 8.9% of the worldwide population is suffering from hunger accordingto FAO, therefore, depleting the planet's natural resources. It is critical to broaden our understanding of the issue to transform the food system and raise public awareness that motivate change. PRECIOUS aims to contribute to the transformation of food systems by addressing existing data gaps and developing a unified and openly accessible evaluation framework to quantify the economic, environmental, and social impacts of strategies to reduce FLW, taking into account potential rebound effects. The project will engage stakeholders from 2 Use Cases (Spain and Greece) and 3 Co-creation and Replication Nodes (Poland, Lithuania, Hungary) to address systemic causes across geographical boundaries. The project aims to induce a fundamental change in attitudes and behaviours towards food consumption and disposal through collaborative efforts and innovative methods, fostering a more just and sustainable EU food system.

Keywords: ghg emissions climate change adaptation,
Unravelling the eukaryotic post-transcriptional regulatory code (EPIC)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Synergy grants
Action type: ERC actions
Countries involved: Belgium,Germany,Sweden
Call: ERC Synergy Grants (ERC-2023-SyG, 2023)
Start date: 2024-07-01
End date: 2030-06-30
Duration (months): 72.0
Total project cost (EUR): 9989247.0
EU funding (EUR): 9989247.0
Participants: 3
Project status: SIGNED

Genomes encode instructions for cells to regulate gene activity in response to their environment. However, and despite its importance for biology, medicine and biotechnology, the underpinning regulatory code remains undeciphered. Gene regulation consists of two major steps. First, genes are transcribed into mRNA. Second, post-transcriptional mechanisms regulate mRNA stability and the rate at which it is translated into proteins. This second step of gene regulation is still poorly understood because relevant parameters such as mRNA half-life, mRNA protein binding and subcellular localization are difficult to assay. The lack of understanding of post-transcriptional regulation implies that we still do not have a complete picture of the regulatory code. In EPIC, we exploit the advantages of the model eukaryote Saccharomyces cerevisiae and other species covering a broad evolutionary range to derive the first comprehensive sequence-based model of eukaryotic gene regulation. EPIC integrates the complementary expertise of 3 teams. It combines innovative high-throughput technologies (Pelechano) to probe post-transcriptional regulation at an unprecedented scale across a broad range of species and conditions with synthetic biology to massively test regulatory sequences (Verstrepen). Deep learning on these data allows us to build predictive models and unravel complex regulatory instructions (Gagneur). Ultimately, EPIC will enable us to decipher the actual language of gene regulation and facilitate (re)writing genomes. EPIC will enable understanding and predicting regulation, and ultimately phenotype, from DNA, closing a major gap in basic biology, while also opening exciting avenues for applications in biotechnology and medicine, from pinpointing disease-causing mutations to rational design of genes, RNAs and cells.

Keywords: post transcriptional regulation deep learning rna biology yeast microbiology synthetic biology
TRansformation of AViation and rAirway soLutions toWards Integration and SynergiEs (Travel Wise)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Public-private partnerships
Destination: Europe's Rail
Action type: Innovation actions
Partnership: EU-RAIL (JU-JTI)
Countries involved: Italy,Spain,Sweden,Finland,France,Ireland,Greece,Belgium,Netherlands,Switzerland,Germany
Call: EU-RAIL – SESAR SYNERGY: INTEGRATED AIR AND RAIL NETWORK BACKBONE FOR A SUSTAINABLE AND ENERGY-EFFICIENT MULTIMODAL TRANSPORT SYSTEM (HORIZON-JU-ER-2023-01, 2023)
Start date: 2024-10-01
End date: 2027-09-30
Duration (months): 36.0
Total project cost (EUR): 6571261.43
EU funding (EUR): 4999172.81
Participants: 37
Project status: SIGNED

Travel Wise's will support the shift from traffic management in silos to intermodal traffic orchestration by putting in place a methodology, a roadmap and the related technologies to allow for i) sharing of information between air and rail operators, ii) intermodal collaborative decision making both in nominal situations and in case of disruptions, iii) optimisation of passenger experience. Among others, Travel Wise will exploit the experience acquired in the air sector while building the Single European Sky and the European ATM architecture (EATMA) to share knowledge with the rail sector and support the progressive results of the System Pillar created by ERJU in the building of the European Single Railway Area and in the definition of the Rail System Architecture. To create an intermodal ecosystem and following the evolution of the ATM and rail sectors and their Master Plans, Travel Wise will exploit the full benefits of digitalisation, define a roadmap towards a common air-rail data space, extend the Collaborative Decision Making process to multimodality, develop integrated operations plans, and design, develop, implement and validate technical solutions for air-rail integrated traffic management in both nominal and non-nominal situations. This is guaranteed by the presence in the consortium of relevant members of both Joint Undertakings and a wide representation of end users ranging from airport and rail infrastructure managers, air and rail operators, air navigation service providers (ANSPs), other transport mode operators, relevant technology providers and research centres.

Keywords: multimodality,syncromodality,railways,aviation,integration of transport modes,seamless travelling,operations plan,collaborative decision making
EXCELlent Science with Impact, Open and Reliable (EXCELScIOR)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Attracting and mobilising the best talents
Destination: Attracting and mobilising the best talents
Action type: Coordination and support actions
Countries involved: Portugal
Call: ERA Chairs (HORIZON-WIDERA-2022-TALENTS-01, 2022)
Start date: 2023-03-01
End date: 2028-02-29
Duration (months): 60.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

EXCELScIOR will develop, extend and fully unlock the research potential of the University of Coimbra (UC, Portugal) through the implementation of a new interdisciplinary ERA Chair devoted to Meta-research (i.e., “research on research”, or Meta-science). Meta-research fosters reproducibility and interdisciplinarity, making science more efficient through better use of research data, more reliable through better verification and ultimately more transparent (open) and responsive to societal challenges and needs. EXCELScIOR strategic goal is thus to improve UC’s research methods and practices, and enhance approaches to integrate information, generate reliable evidence and maximize its impact, in order to increase the scientific production, quality and organizational praxis of Research & Innovation at UC towards EU/ERA excellence. Biomedical Sciences will be the ERA Chair’s primary target during the project’s execution, but the intrinsic nature of meta-research is seemingly apposite and will then continue to revolutionize and advance multiple other research areas, within UC and beyond. The named ERA Chair holder _ Professor John Ioannidis from the University of Stanford _ is considered a pioneer in meta-research, being one of the ten most-cited scientists globally across all sciences. His work in the field attained worldwide recognition and has transformed research in biomedicine and multiple other scientific areas. Under his leadership, this ERA Chair will strive and, in the long term, evolve into a new research to action center _ the Meta-Research Innovation Center - Coimbra (METRIC C) _ bound to operate in tandem with the Meta-Research Innovation Center at Stanford (METRICS) and its sister in Berlin (METRIC-B), both of which co-founded and (co-)directed by Professor Ioannidis.

Keywords: meta research research methods and practices open science research reproducibility biomedical sciences cross disciplinarity
HIGH-RESOLUTION FUNCTIONAL OPTICAL IMAGING OF CHEMORESISTANCE (CHEM-SCAN)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Pathfinder
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Germany,Belgium,France,Austria
Call: EIC Pathfinder Open (HORIZON-EIC-2025-PATHFINDEROPEN, 2025)
Start date: 2026-03-01
End date: 2030-02-28
Duration (months): 48.0
Total project cost (EUR): 2998207.5
EU funding (EUR): 2998207.5
Participants: 5
Project status: SIGNED

The development of chemoresistance, i.e. the ability of cancer cells to evade treatment, has become a major challenge for current cancer therapy and significantly contributes to most tumor relapses and deaths. Changes in the way how sub-populations of cancer cells process metabolites have been identified as an indication of tumor chemoresistance: multiple different metabolites were found and identified in several chemoresistant tumors, which are attributed to facilitate tumor cell survival under chemotherapeutic stress. Identifying cells that can resist chemotherapy by adapting metabolite processing is, however, difficult, because this requires assessing the biochemical state of many cells at the single cell level and for multiple metabolites, simultaneously. A key limitation is that currently no single non-invasive platform exists that can be utilized in a highly parallelized fashion to monitor chemoresistance at the cellular and tissue level. CHEM-SCAN will develop novel fluorescent probes for the energetic/reductive state of cells, metabolites, and metabolic indicators that can assess chemoresistance of single cells. These probes will be assessed with highest sensitivity and spatiotemporal resolution by CHEM-SCAN's novel high-speed fluorescence lifetime imaging (FLIM) platform across multiple length scales. This FLIM platform will allow biomedical and clinical researchers to determine and follow the individual responses of human cancer cells to chemotherapy, enabling the assessment of individualized treatment options. Using the platform, alternative options for the individualized treatment of chemoresistant tumors, such as the combination of multiple drugs or the testing of new drugs can rapidly be conducted in-vitro without posing additional burdens on the patient. At the same time, CHEM-SCAN will provide a research platform for the continued quest for a better understanding of chemoresistance and will be able to scale well beyond just this initial target.

Keywords: functional fluorescent probes,chemoresistance,fluorescence lifetime imaging,high resolution optical imaging
The malaria chemical atlas: Revealing the parasite-host functional interactome (MalChemAtlas)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Immunity, Infection and I mmunotherapy
Panel description: The immune system , related disorders  and their mechanisms , biology of infectious agents and infection, biological basis of prevention and treatment of infectious diseases , innovative imm unological tools and approaches , including  therapies
Countries involved: Israel
Call: ERC CONSOLIDATOR GRANTS (ERC-2022-COG, 2022)
Start date: 2023-10-01
End date: 2028-09-30
Duration (months): 60.0
Total project cost (EUR): 2000000.0
EU funding (EUR): 2000000.0
Participants: 1
Project status: SIGNED

Malaria is the most life-threatening parasitic disease in humans. Invasion of the malaria parasite, Plasmodium falciparum (Pf), into the blood circulation rewires the harmonious networking between the resident cells. Until recently, Pf was not thought to be able to communicate when nested within infected human red blood cells (RBCs). However, we and others have laid the foundations of Pf communication via extracellular vesicles. We now hypothesize that in order to survive in the hostile host environment, Pf secretes chemical inducers (e.g., metabolites, peptides) to actively coordinate life decisions as a group and to control the surrounding host cells. Remarkably, we obtained proof-of-principle preliminary results in the form of an isolated, active chemical fraction that inhibits Pf population growth in a density-dependent manner. Our overarching goal in MalChemAtlas is to expose this yet-to-be-revealed mode of communication in malaria: cell-to-cell chemical signaling. We will combine analytic chemical, biophysical and omics technologies with machine-learning approaches to comprehensively reveal and characterize the functional chemicals that: I) facilitate parasite density, growth and sexual development (parasite-parasite signaling), II) dictate parasite crosstalk with circulating host immune cells and naïve RBCs (parasite-host communication), and III) affect downstream signaling cascades between the host’s innate and adaptive immunity (host-host communication). In this effort, we will leverage our extensive (HPLC-based) analytical fractionation pipeline, combined with NMR and metabolomics analyses, for identifying malaria-secreted autoinducers. Our preliminary findings demonstrate the potential of our basic research to be applied to the translational level of intervention. Identifying “natural chemical killers” offers a previously unexplored direct strategy to fight malaria - the highest gain we can ask for when researching this deadly disease.

Keywords: cell cell chemical communication,pathogen host interaction,microbiology,quorum sensing,extracellular vesicles
Personalised Health cognitive assistance for RehAbilitation SystEm (PHRASE)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Transition
Destination: Challenges
Action type: EIC actions
Countries involved: Spain,Germany,Belgium,Netherlands
Call: Medical Technology and Devices: from Lab to Patient (HORIZON-EIC-2021-TRANSITION-CHALLENGES-01, 2021)
Start date: 2022-04-01
End date: 2025-07-31
Duration (months): 40.0
Total project cost (EUR): 2496675.0
EU funding (EUR): 2496674.0
Participants: 5
Project status: SIGNED

Stroke-caused cognitive and neuromotor impairment is currently an increasing burden: post-stroke deficits are commonly believed to be treated with rehabilitation. Direct medical costs of stroke are stimated to increase up to 94.3 billion USD only in US. The indirect costs, including non-healthcare costs, are estimated at 15.9 billion. The journey towards recovery includes several stages, from hospitalization to in-patient and out-patient rehabilitation and the subsequent return to home. Not everyone has access to rehabilitation programs, and the gains of them tend to deteriorate after hospital discharge. Focused stroke rehabilitation reduces long-term disability and the economic burden of stroke and supports prevention by lessening modifiable risks. The objective of PHRASE (Personalised Health cognitive assistance for RehAbilitation SystEm) is to create a workflow that integrates the best available scientific knowledge and obtain an efficient prognosis and intervention protocols for stroke and other brain-related diseases. It will not only allow to treat stroke-caused impairments better and more efficiently, but also it is a potential treatment for other neurological diseases like dementia, aphasia and PSCI, depression or multiple sclerosis. Eodyne's PHRASE will be based on RGS previous technology, developing its Technology Readiness Level. The present consortium brings together a comprehensive group of highly qualified experts. So that Eodyne can successfully produce prognosis and intervention individualized protocols, EBRAINS will be the brain database and Charité will provide with its brain models for the combination of data brain. SPECS-Lab will bring its knowledge in cognitive rehabilitation and will act as clinical coordinator, while Saddlepoint Science brings the expertise to implement the AI tools for continuous improvement of the intervention protocols.

Keywords: stroke,cognitive rehabilitation,interventional tools,data pipeline
Heparanase inhibition as a multifunctional targeting approach in cancer (HEPINIB)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Staff Exchanges
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany,France,Sweden,Israel,Italy,Estonia,Argentina
Call: MSCA Staff Exchanges 2021 (HORIZON-MSCA-2021-SE-01, 2021)
Start date: 2023-01-01
End date: 2026-12-31
Duration (months): 48.0
Total project cost (EUR): 490228.57
EU funding (EUR): 437000.0
Participants: 12
Project status: SIGNED

Cancer is a leading cause of mortality within the aging European population. Therapeutic targeting is hampered by the complexity of the disease, which includes not only molecular changes within the tumor cell itself, but also within its microenvironment. Tumor angiogenesis, tumor-stroma interactions, interactions with immune cells, with the extracellular matrix and cancer stem cell niches allow for malignant cell survival and promote metastasis, the leading cause for cancer-associated mortality. Proteins substituted with the heparin-related carbohydrate heparan sulfate (HS) are dysregulated in malignant diseases, and are known to modulate all of the aforementioned processes of tumor progression. Several functions of HS-PGs in tumor progression are modulated by the enzyme heparanase (HPSE), which is barely expressed in adults, but upregulated during tumor progression, inflammation and angiogenesis, thus constituting an excellent drug target. Indeed, HPSE, the sole HS degrading endoglycosidase, regulates multiple biological activities that enhance tumor growth, metastasis, angiogenesis and inflammation. HPSE accomplishes this by degrading HS and thereby regulating the bioavailability of heparin-binding proteins, priming the tumor microenvironment and mediating tumor-host crosstalk. We predict that therapeutic targeting of HPSE to be superior to conventional approaches, as it does not only have the potential to synchronously targeting tumor progression and metastasis at multiple levels (metastasis, angiogenesis, inflammation & immunity), but it is also be expected to have a favourable side effects profile. HEPINIB will combine leading experts of HPSE-related cancer research with non-academic partners providing a panel of innovative technologies with the aims of providing a deeper understanding of HPSE function in tumor progression, of developing novel HPSE inhibitors and delivery systems, and of trans-sectoral and interdisciplinary training of young scientists.

Keywords: heparanase,glycosaminoglycans,heparin,proteoglycans,heparan sulfate